Hung‐Chih Hsu

A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer

J.S. Chen, Chih‐Hung Hsu, Nai‐Jung Chiang et al. · Annals of Oncology · 2015 · 157 citations

Gastrointestinal Oncology, Medicine, Biliary Cancer +7

Mutations of <i>KRAS/NRAS/BRAF</i> predict cetuximab resistance in metastatic colorectal cancer patients

Hung‐Chih Hsu, Tan Kien Thiam, Yen‐Jung Lu et al. · Oncotarget · 2016 · 126 citations · Full text

Overexpression of Lgr5 correlates with resistance to 5-FU-based chemotherapy in colorectal cancer

Hung‐Chih Hsu, Yi‐Shiuan Liu, Kai-Chi Tseng et al. · International Journal of Colorectal Disease · 2013 · 87 citations

Tumor Biology, Medicine, Lgr5 Correlates +8

Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial

Kanwal Raghav, Salvatore Siena, Atsuo Takashima et al. · The Lancet Oncology · 2024 · 87 citations

Oncology, Gastrointestinal Oncology, Primary Results +7

Lgr5 promotes cancer stemness and confers chemoresistance through ABCB1 in colorectal cancer

Yi‐Shiuan Liu, Hung‐Chih Hsu, Kai-Chi Tseng et al. · Biomedicine & Pharmacotherapy · 2013 · 67 citations

Tumor Biology, Cancer Stemness, Medicine +9